-

Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the Wells Fargo 21st Annual Healthcare Conference in Boston on Wednesday, September 9, 2026, at 2:15 p.m. (Eastern Time).

The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit insulet.com or omnipod.com.

©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved.

Contacts

Investor Relations:
Clare Trachtman
Vice President, Investor Relations
ir@insulet.com

Media:
Joan Campion
Vice President, External Communications
pr@insulet.com

Insulet Corporation

NASDAQ:PODD

Release Versions

Contacts

Investor Relations:
Clare Trachtman
Vice President, Investor Relations
ir@insulet.com

Media:
Joan Campion
Vice President, External Communications
pr@insulet.com

Social Media Profiles
More News From Insulet Corporation

Insulet Reports Second Quarter 2026 Results

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended June 30, 2026. Second Quarter Financial Highlights: Revenue of $801.7 million, up 23.5%, or 22.7% in constant currency, and exceeded the high end of the Company’s guidance range of 20% - 22% at constant currency rates Total Omnipod revenue of $795.9 m...

Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced a global partnership with Calm, a leading consumer mental health company, to provide emotional well-being resources for people living with diabetes, their caregivers, and healthcare professionals. The partnership launches Calm’s first-ever integrated content partnership and collection with a MedTech...

Insulet Accelerates Global Growth with Launch of Omnipod® 5 and Omnipod Discover™ in Spain, Expanding Access to Tubeless Diabetes Technology

ACTON, Mass.--(BUSINESS WIRE)--Insulet Accelerates Global Growth with Launch of Omnipod 5 and Omnipod Discover in Spain, Expanding Access to Tubeless Diabetes Technology...
Back to Newsroom